OVERVIEW

 

Therome Innovation Partners, LLC is a pre-clincial stage biomedical start-up company specializing in innovative ocular therapeutic medicine to help patients suffering from age-related macular degeneration and diabetic retinopathy. Through investors and partnerships, we aspire to make our liposomal drug delivery system the leading solution for patients suffering from these damaging diseases.

 

This delivery system focuses on patient needs by offering fewer injections each year and lower chances of infection. The pre-clinical testing has shown promising results and it is Therome's vision to take this drug delivery system into clinical testing. 

VENTURE STATUS 

AND ACHIEVEMENTS

 

- In vitro studies for drug release kinetics

- Formulation stability studies

- Animal studies for in vivo drug release kinetics

- Cytotoxicity and histopathology studies

- Granted patent (US 9962333 B2) and several continuation patents under review

- Currently developing coatings and hydrogels for controlled release

CURRENT PATENTS

ON LIPOSOMAL DELIVERY SYSTEM

 

US996233B2

US 2018/221483 A1 (pending)

US 2019/0307691 A1 (pending)